MK

Mark Krul

Director Aglaia Oncology Funds

The Randstad, Netherlands

Investor
VC
Founder

Invests in

Stages:

Series A
Seed

Locations:

Netherlands

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Immunology
Oncology
Cancer
Vaccines
Biotechnology
Life Sciences
R&D
Pharmaceuticals
Biopharmaceuticals
Molecular Biology
Lifesciences
Drug Development
Technology Transfer
Drug Discovery
Genomics
Pharmaceutical Industry
Clinical Development
Cell
Infectious Diseases
Clinical Trials

Education

Lists including Mark

AM
Al
AF
AV

Based in Amsterdam

273 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Inthera Bioscience

Seed

Total Funding: $20M

Cristal Therapeutics

Series Unknown

Total Funding: $14M

Work Experience

OA
Oncode Accelerator

2024

  • Chief Scientific Officer

    2024

CT
Cristal Therapeutics

2017

  • Board Member

    2017

IB
Inthera Bioscience AG

2018

  • Chief Executive Officer

    2024

  • Board Member

    2018 - 2024

AO
Aglaia Oncology Fund II

2003

  • Founder and Director

    2014

  • Director

    2003

M-
MIMETAS - The Organ on a Chip Company

2018 - 2022

  • Board Member

    2018 - 2022

Macrophage Pharma Ltd.

2017 - 2022

  • Board Member

    2017 - 2022

IP
ISA Pharmaceuticals B.V.

2004 - 2018

  • Chairman Advisory Board

    2004 - 2018

NDDO Oncology

1997 - 2003

  • Manager drug development

    1997 - 2003

European Cancer Center

1993 - 1997

  • Research Manager

    1993 - 1997